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Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is one of the leading infectious disease causes of morbidity
and mortality worldwide. Though current antibiotic regimens can cure the disease, treatment requires at least six months of
drug therapy. One reason for the long duration of therapy is that the currently available TB drugs were selected for their
ability to kill replicating organisms and are less effective against subpopulations of non-replicating persistent bacilli.
Evidence from in vitro models of Mtb growth and mouse infection studies suggests that host immunity may provide some
of the environmental cues that drive Mtb towards non-replicating persistence. We hypothesized that selective modulation
of the host immune response to modify the environmental pressure on the bacilli may result in better bacterial clearance
during TB treatment. For this proof of principal study, we compared bacillary clearance from the lungs of Mtb-infected mice
treated with the anti-TB drug isoniazid (INH) in the presence and absence of an immunomodulatory phosphodiesterase 4
inhibitor (PDE4i), CC-3052. The effects of CC-3052 on host global gene expression, induction of cytokines, and T cell
activation in the lungs of infected mice were evaluated. We show that CC-3052 modulates the innate immune response
without causing generalized immune suppression. Immune modulation combined with INH treatment improved bacillary
clearance and resulted in smaller granulomas and less lung pathology, compared to treatment with INH alone. This novel
strategy of combining anti-TB drugs with an immune modulating molecule, if applied appropriately to patients, may
shorten the duration of TB treatment and improve clinical outcome.
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Introduction
Tuberculosis (TB) remains a major global public health problem:
Approximately 2 billion people are currently infected, with over 9
million new TB cases and 1.3 million deaths occurring each year
[1]. Although the majority of individuals infected by Mycobacterium
tuberculosis (Mtb) do not develop primary active disease,manyremain
latently infected with a potential for reactivation later in life [2].
Reactivation of latent TB forms a large potential source of new
infections. TB chemotherapy is generally efficacious, but current
drug regimens require a minimum of six months to achieve cure.
Moreover, treatment is often associated with drug toxicities and
drug-drug interactions, especially in HIV co-infected patients
receiving antiretroviral therapy [3]. If treatment is interrupted or
inadequate, the risks of relapse and/or development of drug
resistance are high. The availability of effective shorter drug
regimens for treatment of TB would greatly reduce these risks and
would contribute significantly to improving TB control.
The long duration of therapy required for cure has been
attributed to the presence of phenotypically heterogeneous
populations of bacilli in infected tissues, including subpopulations
of organisms that are not responsive to antibiotics [4–7]. These
bacillary subpopulations are thought to be in a slow or non-
replicating state, rendering them less responsive to the action of
anti-TB drugs, many of which were selected for the ability to kill
actively growing bacilli [2,8]. Non-replicating persistence of Mtb
has been associated with various environmental conditions present
in infected host tissues, such as low oxygen tension and limited
nutrient availability [9–11]. In addition, several studies have
implicated reactive nitrogen intermediates (RNI), including nitric
oxide (NO), produced by activated macrophages, as an important
environmental cue directing the shift of Mtb towards dormancy
[12–14].
Thus, the host immune response may, to some extent, hinder
TB treatment by driving a subpopulation of the bacilli into an
altered metabolic state, in which they are less responsive to
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available from clinical trials using immune modulators as
adjunctive therapy in treatment of pulmonary TB [15,16]. Several
reports have described accelerated sputum culture conversion in
pulmonary TB patients receiving adjunctive corticosteroids
together with antibiotics in comparison with patients who received
antibiotic treatment alone [17–19]. In one recent study, adjunctive
etanercept (soluble TNF-receptor) resulted in reduced time to
sputum culture conversion and improved clinical signs in HIV-
infected TB patients [20].
To investigate whether immune pressure can affect the
responsiveness of Mtb to isoniazid (INH) and to test whether
immunity can be modified to improve treatment efficacy, we used
the mouse Mtb aerosol infection model and evaluated the
effectiveness of INH treatment in the presence and absence of
an immune modulator. For these experiments, we used a novel
phosphodiesterase 4 inhibitor (PDE4i) to modulate the host
immune response. PDE4 is a member of a diverse family of
enzymes, including 11 distinct isoforms that hydrolyze cyclic AMP
(cAMP) or cyclic GMP (cGMP) [21]. The distribution of PDE
isoforms varies among different tissues and cell types, facilitating
the selective inhibition of specific isoforms, as a means of targeting
specific cell types and/or activities. cAMP is an important
intracellular second messenger which, at increased levels, has
anti-inflammatory and tissue protective effects. The specific PDE4i
compound used in this study was CC-3052, which increases
intracellular levels of cAMP, leading to down-regulation of TNF-a
and other inflammatory cytokines in monocyte/macrophages [22–
24]. CC-3052 is water soluble and has been shown to be non-
toxic, non-mutagenic and non-teratogenic [23]. The drug
demonstrated little or no measurable effect on T cell activation
[25,26], which is consistent with the finding that activation of T
cells is regulated by the isozyme PDE7 but not PDE4 [27]. Thus,
CC-3052 would not be expected to cause generalized immune
suppression. We hypothesized that immune modulation with CC-
3052 would alter the intracellular environment within the infected
macrophage, so that a greater proportion of the bacilli would
remain in a more metabolically active state and would retain their
responsiveness to INH. The effects of CC-3052 on host global
gene expression, induction of cytokines, and T cell activation in
the lungs of infected mice were evaluated. Our results suggest that
selective modulation of the innate immune response with a PDE4i
can favorably alter the kinetics of INH-mediated bacillary killing
and may enhance the efficacy of TB drug therapy.
Results
Effect of CC-3052 on INH-mediated killing of Mtb in lungs
of infected mice
For these studies, we selected two clinical strains of Mtb that
differ in their abilities to induce an immune response in mice and
in human monocytes [28]. Although the growth curves do not
differ substantially in mice, CDC1551 promotes a strong, early
Th1 response and is less virulent in mice, while HN878 is less
immunogenic and highly virulent, causing earlier death of infected
mice. Mice were infected by low dose aerosol infection with Mtb
strain CDC1551 or HN878 and treated with CC-3052 from day 1
post-infection; bacillary growth, measured as colony forming units
(CFU) in the lungs, was evaluated over time (Figure 1). The
numbers of bacilli in the lungs of CDC1551-infected mice treated
with CC-3052 were similar to those observed in untreated control
infected mice, both of which stabilized by about 28 days post-
infection (Figure 1A). Throughout the experiment (84 days), there
were no significant differences in bacterial loads between CC-
3052-treated and untreated mice (P=0.882), suggesting that CC-
3052 treatment of the mice did not accelerate the growth of Mtb in
the lungs. INH treatment, initiated on day 14 post-infection,
initially reduced the CFU efficiently in both experimental groups,
but by 63 days post-infection, the bacterial loads in the lungs of
mice treated with INH alone stabilized at about 2 log10. These
results resemble the characteristic bi-phasic killing curve that was
seen in early studies of INH killing in the mouse [29,30]. In
contrast, the CFU in the lungs of mice co-treated with INH plus
CC-3052 continued to be cleared and at 84 days were significantly
lower in numbers than those in mice treated with INH alone
(P=0.016). Plating of lung homogenates from all experimental
groups on INH-containing solid medium yielded no colonies,
indicating that the residual bacilli in the lungs resulted from
antibiotic tolerance rather than acquired resistance to INH. CC-
3052 treatment alone had no impact on the kinetics of Mtb growth
in broth culture (not shown), demonstrating that the drug has no
direct bactericidal/static effect. Mtb-infected mice treated with
CC-3052 showed no significant reduction in body weight during
the course of the experiment, as compared to untreated control
mice (not shown). A similar pattern of bacillary clearance was
observed in mice infected with Mtb strain HN878, indicating that
the effects of CC-3052 are not Mtb strain-specific (Figure 1B).
Shifting the timing of treatment also did not alter the ability of
CC-3052 to impact bacillary clearance in the lungs. When
CDC1551-infected mice were treated with CC-3052 and INH
beginning on day 14 and day 28 post-infection, respectively, Mtb
killing by INH alone did not slow until 84 days post-infection; the
CFU numbers continued to decline in co-treated mice up until day
112 (Figure 1C).
We evaluated the impact of varying the dose of CC-3052
treatment (5 mg/kg, 25 mg/kg, 100 mg/kg) on the kinetics of Mtb
growth in the lungs of infected mice and found no differences in
the CFU over 28 days (not shown). Importantly, administration of
high dose CC-3052 (100 mg/kg), which is above the pharmaco-
logically active dose (Celgene Corporation, unpublished data), did
not adversely affect the ability of the animals to control Mtb growth
in the lungs.
Effect of CC-3052 on histopathology of Mtb-infected
mouse lungs
Specimens of lung tissue were collected from CDC1551-infected
mice treated with INH from day 14 and/or CC-3052 from day 1;
these were prepared for histopathologic and immunohistologic
analysis. Examination of H&E stained sections from lungs
collected during the first 4 weeks of infection showed minimal
differences among the different experimental groups (not shown).
At 42 days post-infection, the lungs from CC-3052-treated mice
showed somewhat less organized granulomas than those in control
untreated mice, but the differences were not striking (Figure 2).
The lesions in the lungs of untreated mice contained small
aggregates of macrophages (arrows) surrounded by large numbers
of lymphoid cells (Figure 2A and B). In the lesions of these mice,
CD3
+ staining cells were distributed predominantly around the
aggregates of macrophage and accounted for a minority of
lymphoid cells seen in the granulomas (Figure 2C). An average of
171626 CD3
+ T cells were seen in each 640 field of granuloma.
The macrophages contained single or small clusters of acid-fast
bacilli (AFB) (Figure 2D arrows). By comparison, in the
granulomas of CC-3052-treated mice, more diffuse macrophage
aggregates and more evenly dispersed lymphoid cells were seen
(Figure 2E and F). The number of CD3
+ T cells was similar to that
seen in control untreated mouse lungs, with an average of 156622
CD3
+ T cells per 640 field of granuloma (Figure 2G). In CC-
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small clusters of AFB (Figure 2H). In contrast, the lungs of mice
treated with INH alone contained condensed small granulomas
with many lymphoid cells (Figure 2I), with few CD3
+ T cells
(Figure 2J) and few AFB (not shown). CC-3052 plus INH
treatment at 42 days resulted in even fewer and smaller
granulomas (Figure 2K and L), compared to those of mice treated
with INH alone, and a further reduction in the numbers of visible
AFB (not shown).
Morphometric analysis of the extent of the granulomatous
infiltration in the lungs of infected mice showed differences in the
number of granulomas per cm
2 and in the percent of area of the
lung involved in granuloma formation among the different
treatment groups (mean of 3 experiments). At 35 days post-
infection, the average numbers of granulomas per cm
2 in the lungs
of the different treatment groups were: controls, 91.2621.0; CC-
3052, 89.1628.0; INH, 36.768.4; and INH plus CC-3052,
20.6611.3 (Figure S1). The average area of the lung parenchyma
occupied by granulomas was: controls, 25.969.1%; CC-3052,
21.268.3%; INH, 1.760.3%; and CC-3052 plus INH,
1.761.0%. By 63 days post-infection, the extent of pathology
was reduced in all experimental groups. The number of
granulomas and the area occupied in the lungs had declined to:
controls, 41.8619.6 granulomas per cm
2 and 14.366.2% of the
area of the lung involved; for CC-3052, 67.160.1 granulomas per
cm
2 and 8.660.2% of the area of the lung involved. In the INH-
treated animals, the granulomatous response involved: INH,
11.162.9 granulomas per cm
2 and 1.060.3% of the area,
respectively; versus INH plus CC-3052, 3.460.4 granulomas per
cm
2 and 0.260.1% of the area, respectively. Thus, the
combination of CC-3052 plus INH treatment resulted in
significantly lower (P=0.02) lung involvement (percent of the
lung with pathology) compared to INH alone (Figure S1).
Effect of PDE4 inhibition by CC-3052 treatment on host
gene expression in the lungs of Mtb-infected mice
The impact of PDE4 inhibition on gene expression in the lungs
of Mtb-infected mice was evaluated by Affymetrix DNA array.
Mice were infected with CDC1551, with and without CC-3052
treatment initiated on day 1. Total RNA was isolated from the
lungs at 14, 21, 28, and 42 days post-infection to follow temporal
changes in global gene expression. At 14 days post-infection,
relatively few genes (45) were differentially expressed in response to
infection in the absence of PDE4i, based on Significance Analysis
of Microarrays (SAM) with a cut-off of $1.5-fold differences using
Partek Genomics Suite (Table 1). The number of differentially
expressed genes increased by 21 days (767) and was maximal at 28
days (1,130), declining again by 42 days (693) post-infection
(Table 1). This temporal pattern is consistent with what is known
about the host immune response in murine pulmonary TB
infection, which involves initial recruitment of leukocytes to the
site of infection and activation of the pro-inflammatory response,
followed by dampening of the early response, as granulomas are
established and the infection matures into a chronic steady-state
[31,32]. The functional categories of host genes most affected by
Mtb infection included innate immune response, T cell activation,
antimicrobial response, apoptosis and metabolism, based on
analysis by Pathway Express (Figure 3B), consistent with a
previously published study of the murine transcriptional response
to Mtb [33].
Treatment of infected mice with CC-3052 affected the expression
of a accumulative total of 186 genes over the course of infection, of
which 164 were down-regulated and 22 were up-regulated ($1.5
fold), as compared to no treatment (data not shown). The temporal
changes in gene expression induced by CC-3052 were similar to
those due to infection, with relatively minor changes at 14 days (4
genes up-regulated; 33 genes down-regulated), increasing effects at
day 21 (20 up; 114 down) and day 28 (5 up; 158 down), and fewer
genes differentially expressed at 42 days (15 up; 28 down) post-
Figure 1. Effect of CC-3052 on M. tuberculosis bacillary load in
lungs during INH treatment. B6D2F1 mice were infected by low
dose aerosol (100–200 cfu) with M. tuberculosis clinical isolates
CDC1551 (A and C) or HN878 (B) [28]. CC-3052 treatment was initiated
on day 1 (A and B) or day 14 (C) (arrow) after infection, and INH
treatment was initiated at 14 days (A and B) or day 28 (C) post-infection
(dotted line). Results are the mean CFU6SD of 2–6 independent
experiments for CDC1551 (A); 2 experiments for HN878 (B) and 2
experiments for CDC1551 (C) (3–4 mice/group/experiment). Treatment
groups: Untreated (open square); CC-3052 treated (filled square); INH
treated (open triangle); CC-3052+INH treated (filled triangle).
* Represents a statistical significant difference (P,0.05) between INH
and CC-3052+INH treated mice.
doi:10.1371/journal.pone.0017091.g001
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Mtb infection alone or CC-3052 treatment at 21 and 28 days post-
infection were compared using Ingenuity Pathway Analysis (IPA),
which includes only annotated genes. Of the genes differentially
expressed in response to CC-3052 treatment, 86.6% (116/134) and
95.7% (156/163) overlapped with those whose expression was
affected by Mtb infection (Figure 3A). Many of the genes
differentially expressed by CC-3052 treatment were involved in
the host innate immune response, for example: innate immunity
(cd68, clec4e, clec5a, clec7a, clec12, ly86, irg1, tlr7, c1qa, c1qb, c1qc),
inflammatory response (ccl3, ccl8, cxcl5, cxcl9, cxcl10, ccr5, cxcr6, ifn-c,
il-1a, il-1b, tnf-a, tnfaip2, tnip3), immune regulation (aoah)a n d
Figure 2. Effect of CC-3052 on histopathology of CDC1551-infected mouse lungs with or without INH. Treatment with CC-3052 was
initiated from day 1 and INH was administered from day 14 after infection. Sections of lungs of mice infected for 42 days are shown. The arrows show
accumulation of macrophages (H&E: A, B, E, F, I, K) or the presence of AFB (ZN: D, H). CD3
+ T cells are brown (anti CD3 monoclonal Ab: C, G, J, L).
Untreated control (A–D); CC-3052-treated (E–H); INH-treated (I, J); CC-3052+INH treated (K, L). Magnification64: A, E, I and K;640: B–D, F–H, J and L.
doi:10.1371/journal.pone.0017091.g002
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resulted in down-modulation of a subset of the same genes that were
up-regulated by infection. The genes that were differentially
expressed in response to CC-3052 treatment belonged to pathways
regulating cytokine-cytokine receptor interaction, Toll-like receptor
signaling, complement and coagulation cascades, graft-versus-host
disease, T cell receptor signaling, and apoptosis (Figure 3B).
Quantitative PCR (qPCR) was used to confirm the differential
expression of a subset of genes associated with the pro-
inflammatory response to Mtb infection (Figure 3C). TNF-a, IL-
1b, NOS2 and IFN-c play a central role in the activation of
macrophages and are essential for host control of Mtb infection
[32,34]. TNF-a, IL-1b and NOS2 are produced by macrophages
in response to infection with Mtb, while IFN-c is produced by
dendritic cells and various lymphoid cells, including lymphoid cells
of the innate immune response. Using the same mRNA pools from
the CC-3052 treated and untreated mice at 21 and 28 days post-
infection, we evaluated the impact of PDE4i treatment on the
expression of these genes. We found that Mtb infection significantly
increased the expression of tnf-a, 2.49/3.01; ifn-c, 2.45/4.11; il-1b,
2.76/3.43; and nos2, 2.69/5.98 at 21 and 28 days post-infection
respectively (differential expression $1.5 fold, P,0.05). In
contrast, CC-3052 treatment resulted in decreased gene expres-
sion: tnf-a, 21.63/21.50; ifn-c, 21.64/21.54; il-1b, 21.67/
21.58; and nos2, 21.68/21.84 at 21 and 28 days post-infection
respectively (Figure 3C). In addition, we used qPCR to compare
the relative expression of a number of other genes which are
known to be regulated by TNF-a, including those encoding
chemokines (cxcl5, cxcl10), TNF-a induced protein 2 (tnfaip2), and
argininosuccinate synthetase 1 (ass1) [35,36]. All of these genes
were up-regulated in response to Mtb infection and down-
regulated by CC-3052 treatment at both 21 and 28 days post-
infection, confirming that TNF-a is a target of PDE4 inhibition.
We also examined the expression levels of a number of genes
which are known to play important roles in innate immunity,
including Toll-like receptor 7 (tlr7), serum amyloid A3 (saa3),
immune responsive gene (irg1), and lymphocyte antigen 86 (ly86)
[33,37–41]. These genes were similarly up-regulated by Mtb
infection and down-regulated by CC-3052 treatment (Figure 3C).
One potential explanation for the impact of CC-3052 treatment
on global gene expression in the infected mice may be that PDE4
inhibition is causing changes in the relative distributions of cell
types in the lungs. To test this possibility, single cell suspensions
were prepared from the lungs at 28 days post-infection and used to
analyze the cellular composition of the tissues by flow cytometry.
Results of this analysis showed that treatment with CC-3052 did
not affect the relative abundance of CD4
+ and CD8
+ T cells and
monocyte/macrophages (CD14
+) in the lungs (Figure S2A and B).
In addition, by staining the cell suspensions for intracellular IFN-c
and analyzing by flow cytometry, we showed that the percentages
of CD4
+ and CD8
+ T cells producing IFN-c in the lungs were
unaffected by CC-3052 treatment (Figure S2C).
Effect of CC-3052 treatment of mice on Mtb-induced
spleen T cell activation
The impact of CC-3052 on Mtb-specific activation of CD4
+ and
CD8
+ T cells in chronically infected mice (42 days), at the time when
acquired immunity is fully established, was evaluated. Single cell
suspensions prepared from spleen were stimulated ex vivo with ConA
or Mtb CDC1551 for 6 days, and T cell proliferation was measured
by the carboxyfluorescein succinimidyl ester (CFSE) flow cytometry
assay. The capacity of CD4
+ and CD8
+ T cell to proliferate in
response toConA or CDC1551 stimulation was similarin spleen cells
from the infected mice with or without CC-3052 treatment (Figure 4).
Our observations suggest that CC-3052 does not interfere with T cell
activation, consistent with published reports [25,26].
Effect of CC-3052 treatment on monocyte/macrophage
activation
To evaluate the impact of CC-3052 on monocyte/macrophage
activation, the ability of CD14+ cells to produce TNF-a in response
to ex vivo stimulation was assessed by flow cytometry. Single cell
suspensions from spleens of untreated and CC-3052-treated mice
werecollectedat 21 dayspost-infection and stimulated ex vivo for 6 h
by PPD or LPS. The percentage of CD14
+ cells producing TNF-a
was significantly lower in spleens from CC-3052 treated mice than
those from untreated infected control mice following ex vivo
stimulation with PPD (P=0.05) or LPS (P=0.04) (Figure 5A and
B). These data confirm that CC-3052 targets monocyte/macro-
phage function and support the results of the gene expression
profiling, indicating that treatment of Mtb-infected mice with the
PDE4i causes modulation of innate immunity. Taken together, the
results of the ex vivo stimulation experiments suggest that CC-3052
modulates the innate immune response, without affecting T cell
activation, indicating that the drug is not generally immune
suppressive, as previously described [25,26].
Effect of anti-TNF-a antibody (TN3-19.12) on the mouse
response to Mtb infection
As a comparison with the selective inhibition of monocyte/
macrophage TNF-a induced by treatment of mice with CC-3052,
we evaluated the impact of treatment with a monoclonal anti-TNF-
a neutralizing antibody (TN3-19.12) on Mtb infection of mice [42].
Mice infected with CDC1551 were treated with IgG1, TN3-19.12
and/or INH starting at 14 days post-infection. In response to
treatment with TN3-19.12 alone, Mtb continued to grow logarith-
mically in the lungs, reaching levels of 9 log10 CFU at 35 days post-
infection, after which none of the mice in this treatment group
survived (Figure 6A). In contrast, the infection was controlled in
lungs of untreated mice, achieving a steady state of about 6 log10
bacilli from 28 days post-infection to the end of the experiment
(Figure 6A). In mice treated with INH, bacillary loads decreased
similarly in both the TN3-19.12 and control IgG1 co-treated
animals. In addition, treatment of mice with TN3-19.12 alone
resulted in progressive weight loss. By 14 days of treatment (28 days
post-infection), mice had lost more than 20% of their body weight
and were moribund (not shown). The combination of high bacillary
burden and severe weight loss in the TN3-19.12-treated animals
Table 1. Number of Differentially Regulated Genes.
14 d 21 d 28 d 42 d
A. Gene sets regulated by Mtb infection
Up 41 700 1025 683
Down 4 67 105 10
B. Gene sets regulated by CC-3052 treatment
Up 4 20 5 15
Down 33 114 158 28
Gene expression was analyzed from total RNA of uninfected and Mtb-infected
mouse lungs, treated or not treated with CC-3052. Results are representative of
4 independent arrays per group and presented as relative gene expression.
Number of differentially regulated genes was determined based on cutoff of
P,0.05 and $1.5 fold change using Partek Genomics Microarray.
doi:10.1371/journal.pone.0017091.t001
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treatment). In contrast, mice in the other treatment groups gained
weight similarly over time. The expression levels of genes encoding
TNF-a, IFN-c and NOS2 in the lungs of mice treated with TN3-
19.12 at 28 days post-infection, were significantly reduced
compared to the control IgG1 treated animals (Figure 6B).
Impact of TN3-19.12 on gross appearance and
histopathology of CDC1551-infected mouse lungs
The effect of TNF-a inhibition with TN3-19.12 on gross lung
appearance was compared to the effect of inhibition with CC-
3052. Lungs from CDC1551-infected mice treated from day 14
with IgG1 (control), CC-3052, or TN3-19.12 with or without INH
Figure 3. Analysis of transcriptional profile by gene ontology and cytokine mRNA levels by qPCR. Lungs from CDC1551-infected mice
treated with CC-3052 or untreated at 21 or 28 days post-infection were used to prepare mRNA. (A) Venn diagram of genes differentially expressed in
lungs of uninfected versus Mtb-infected mice (open) or Mtb-infected mice treated with CC-3052 versus untreated (shaded) at 21 and 28 days post-
infection. The number of genes was calculated based on $1.5 fold change and P,0.05 cutoff using Partek Genomic Suite. Four independent arrays
per group were performed. (B) Gene ontology of global response and immune response to infection and to CC-3052 treatment in mouse lungs was
analyzed using Pathway Express. (C) mRNA levels of selected cytokine genes using qPCR to validate DNA array data listed in Table S1. PCR was
performed with the same RNA samples in duplicate independently from 4 mice per experimental group. Results of the qPCR are represented as mean
6 SD. The gene ID numbers and gene definitions may be viewed at http://www.ncbi.nlm.nih.gov.
doi:10.1371/journal.pone.0017091.g003
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harvested from CC-3052 treated mice were slightly enlarged
compared to those from IgG1 control mice (Figure 6C). In
contrast, the lungs from TN3-19.12-treated mice were strikingly
enlarged, with numerous large granulomatous lesions not seen in
the IgG1 control or CC-3052-treated mouse lungs (Figure 6C).
INH treatment resulted in a clear reduction in lung size and lesion
size in all treatment groups.
Histopathologic evaluation of lungs at 35 days post-infection in
both control and CC-3052-treated mice revealed similar, well
organized granulomas, with small clusters of AFB clearly visible
(Figure 7A, C, D and F). The granulomas of CC-3052 treated
Figure 4. Effect of CC-3052 on proliferation of spleen T cells. Spleen cells from CDC1551-infected mice treated with CC-3052 or untreated
were harvested at 42 days post-infection, labeled with CFSE and stimulated in culture for 6 days with heat-killed CDC1551 (black), ConA (5 mg/ml)
(blue), or left unstimulated (red). Cells were stained with anti-CD4 and anti-CD8 antibodies. Proliferation was measured as a reduction in CFSE
fluorescence intensity. (A) Proliferating lymphocytes are displayed as histograms. One representative mouse per group is shown. (B) The percent of
CD4
+ and CD8
+ proliferating cells from 3 mice per group are presented as a mean 6 SD.
doi:10.1371/journal.pone.0017091.g004
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more evenly distributed lymphocytes than those in control animals
(Figure 7B and E). In contrast, mice treated with TN3-19.12 had
large granulomas with many polymorphonuclear neutrophils
(PMNs) (Figure 7G) and extensive necrosis (Figure 7H). Extremely
high numbers of AFB were detected in the granulomas of these
mice (Figure 7I). By comparison, co-treatment with TN3-19.12
plus INH resulted in smaller, well-organized lung granulomas,
with higher numbers of lymphocytes and few to no AFB (Figure 7J,
K, and L).
Figure 5. Effect of CC-3052 on intracellular TNF-a in spleen cells. (A) Percent of CD14
+ spleen cells producing intracellular TNF-a at 21 days
post-infection after in vitro stimulation with PPD (P=0.05), LPS (P=0.04), or None (unstimulated). Data shown are the mean 6 SD of three mice per
time point. Untreated mice (open columns) and CC-3052-treated mice (closed columns). * Represents a statistically significant difference (P,0.05)
between untreated controls (UN) and CC-3052 (CC) treated mice. P values were calculated using the unpaired t test. (B) Representative contour
density plot for PPD stimulated cells.
doi:10.1371/journal.pone.0017091.g005
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We have shown that modulation of the immune response in
CDC1551 or HN878-infected mice with the PDE4i CC-3052
improves INH-mediated Mtb killing in the lungs. This was
demonstrated by the clearance of Mtb in INH plus CC-3052 co-
treated animals, which continued to decline up to the end of the
infection, in contrast with clearance during the first 2 months of
treatment in INH only treated mice, where Mtb killing reached a
plateau before the end of the experiment. Thus, while the rate of
bacillary clearance was similar in both treatment groups, the
extended duration of killing in the CC-3052 co-treated mice
resulted in a difference of approximately 2 log10 in CFU, as
compared to INH treatment alone, at later time points. The
continued clearance of bacilli is similar to the impact of adding
pyrazinamide (PZA), which is more active against non-replicating
bacilli, to an INH monotherapy regimen, as described in previous
studies on treatment of Mtb-infected mice [30,43]. Although it is
not clear whether CC-3052 co-treatment can improve the efficacy
of multidrug TB therapy, the use of a host-targeted drug has a
considerable benefit because Mtb cannot develop genotypic
resistance to a drug that targets host function. In our study, we
did not evaluate the ability of co-treatment with CC-3052 plus
INH to achieve sterilization of the bacilli. Larger and more
extensive experiments to test whether these mice can reactivate the
infection upon discontinuation of treatment and general immune
suppression studies are needed to answer this question.
Treatment with CC-3052 alone had no impact on Mtb growth
in vitro or in vivo, indicating that the drug itself is not bactericidal/
static and does not enhance bacillary replication. Rather, we
suggest that down-modulation of the host innate immune response
may have dampened some environmental signals that normally
drive a subset of bacilli into a less metabolically active state, in
which they are not responsive to INH-mediated killing. This
would explain why the enhanced efficacy of INH-mediated killing
by CC-3052 was manifested only at later time points, when the
rate of bacillary clearance mediated by INH alone slowed down,
resulting in the bi-phasic killing curve. This hypothesis must now
be confirmed in experiments to evaluate the physiologic state of
the bacilli in the lungs of mice treated with CC-3052.
The results of the host gene expression studies showed that
treatment with CC-3052 resulted in down-regulation of a subset of
immune response genes that were up-regulated in response to Mtb
infection. These included many genes that are involved in innate
immunity and inflammation. This result is consistent with our
observations that T cell activation was unaffected in mice treated
with CC-3052 alone, and that these mice were fully capable of
controlling the infection by 3–4 weeks, the time at which the
adaptive immune response is optimally induced. It was interesting
to find that the expression of nos2, which is responsible for
macrophage production of NO, was significantly lower in the
lungs of mice treated with CC-3052 at 21, 28 and 42 days post-
infection. As NO has been implicated in the induction of Mtb non-
replicating persistence [12,13,31], it is intriguing to speculate that
reduction of NO by CC-3052 treatment may partially explain the
improved bacillary clearance. This possibility is supported by the
recent identification of a novel antimicrobial primarily active
against non-replicating organisms, which targets Mtb dihydrolipa-
mide acyltransferase (DlaT), an enzyme necessary for resistance to
RNI-induced stress [44]. It is also of interest to note that Mtb
secretes endogenous cAMP, shown to increase the levels of host
TNF-a production [45]. Agarwal et al suggest that their findings
may provide a mechanism by which Mtb itself may contribute
towards eliciting granuloma formation as part of its survival
program.
Small molecule PDE4i penetrate the plasma membrane and act
to increase cAMP levels within the cells [22], reducing production
of TNF-a and other innate immune mediators within the
macrophage. Thus, treatment with CC-3052 resulted in limited
effects on the innate immune response, rather than generalized
Figure 6. Effect of TN3-19.12 on bacillary load, cytokine
production and gross pathology. IgG1 (arrow), TN3-19.12 (arrow)
and/or INH treatment (dotted line) were initiated at 14 days post-
infection. (A) Bacillary load in mouse lungs. Open diamond, IgG1; Closed
diamond, TN3-19.12; Open circle, INH; Closed circle, TN3-19.12+INH,
Results are the mean 6 SD of 3–4 mice per time point per treatment
group. (B) qPCR on mouse lungs collected 28 days post-infection.
Results are the mean 6 SD of 3–4 mice per time point per treatment
group; IgG1- open bars, TN3-19.12- filled bars. * Represents a value of
P,0.05 for TN3-19.12 relative to the IgG1 treated mice (control). (C)
Gross appearance of the lungs from mice treated with IgG1 (control),
TN3-19.12 or CC-3052, with or without INH co-treatment, at 35 days
post-infection.
doi:10.1371/journal.pone.0017091.g006
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monoclonal antibody (TN3-19.12) resulted in immune suppression
leading to loss of control of bacillary growth in the lungs of infected
mice, with extensively increased pathology and greatly accelerated
mortality. Anti-TNF-a monoclonal antibodies would not be
expected to penetrate the plasma membrane, but rather act
extracellular to bind and inactivate any available TNF-a. Since
TNF-a is essential for orchestrating both the innate and acquired
immune response, the complete neutralization of TNF-a would be
expected to lead to a generalized immune suppression in the
animal as seen here. Previous studies have shown that depletion of
TNF-a by treatment of mice with anti-TNF-a antibodies leads to
Figure 7. Effect of CC-3052, TN3-19.12, or INH on histopathology of lungs from CDC1551-infected mice. Treatment with IgG1,
monoclonal anti-TNF-a antibody (TN3-19.12), CC-3052 and/or INH was initiated at 14 days post-infection and lungs were harvested at 35 days post-
infection and histologic analysis was done. (A–C) IgG1-treated (control); (D–F) CC-3052-treated; (G–I) TN3-19.12 treated; (J–L) TN3-19.12+INH treated.
Left panel, H&E64; Middle panel, H&E640; Right panel; ZN640. Arrows indicate granulomas (left panel), macrophages (middle panel) and AFB (right
panel).
doi:10.1371/journal.pone.0017091.g007
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patients with inflammatory disorders with the anti-TNF-a
monoclonal antibody Infliximab has led to increased incidence
of reactivation TB [48].
We also found that the combined effects of CC-3052 and INH
resulted in a reduction in lung inflammation and accelerated
resolution of lung pathology, as compared with mice treated with
INH alone. TB is a striking example of TNF-a as a ‘‘double-edged
sword’’. TNF-a plays an essential role in controlling Mtb infection
and disease severity, but this cytokine can also cause chronic
inflammation leading to tissue damage [49,50]. TB patients
initiating antibiotic chemotherapy can experience a transiently
increased inflammation and worsening of disease in association
with an early burst in circulating levels of TNF-a [51–53]. From a
clinical perspective, the limited impact of CC-3052 on TNF-a
production by monocyte/macrophages is an advantage. The
normal activation of T cells, which requires some TNF-a, ensured
the control of bacillary growth via the contribution of the acquired
immune response to protective immunity in CC-3052-treated
animals. Thus, use of a PDE4i has enabled us to achieve this
critical balance between limiting the negative effects of TNF-a,
while retaining sufficient immunity to control infection. Recently,
the multiple functions of TNF-a in granuloma formation and
control of infection and disease pathogenesis were addressed using
a computer-generated model, which predicted that a critical
balance of TNF-a bioavailability must be maintained in order to
achieve reduction of inflammation while retaining resistance to
infection and microbial disease [54]. We propose that CC-3052 is
a molecule that modulates TNF-a production, without adversely
disrupting this critical balance, and can improve antibiotic-
mediated bacillary clearance. Further studies are needed to
evaluate the impact of PDE4 inhibition in a more clinically
relevant TB regimen of multidrug therapy.
Materials and Methods
Ethics Statement
All animal experimentation was conducted following the Animal
Welfare Act guidelines for housing and care of laboratory animals
and performed in accordance with Public Health Service Policy
Institutionalregulations. Animal ethicsapproval formouseinfection
with M. tuberculosis was obtained from the Institutional Animal Care
and Use Committee at the Public Health Research Institute Center
ofUniversityofMedicine&Dentistry,NewJersey(UMDNJ).PHRI
Center ICPH IACUC approved our study protocol (Approval ID;
071D0810, Role of Immune Pressure in effectiveness of Tubercu-
losis Chemotherapy in the mouse model of TB).
Chemicals and reagents
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO),unlessotherwise stated.PDE4inhibitorCC-3052wassupplied
by Celgene Corporation (Summit, NJ) and prepared as a suspension
in sterile 0.2% carboxylmethylcellulose solution (CMC, Sigma). The
purified monoclonal anti-TNF-a antibody (TN3-19.12) and isotype
control hamster IgG1 antibody were provided by Dr. Robert D.
Schreiber (Washington University in St. Louis, MO) [42].
Infection of mice and drug treatment
Clinical Mtb strains CDC1551 and HN878 were grown to mid-
log phase in Middlebrook 7H9 broth (Difco, Detroit, MI)
containing 10% OADC enrichment (Beckton Dickinson, Franklin
Lakes, NJ), 0.2% glycerol, and 0.05% Tween 80. Animals were
housed in a Biosafety Level 3 pathogen-free facility. In brief, 8 to
10 week–old female B6D2F1 mice (Jackson Laboratory, Bar
Harbor, ME) were infected with low dose (approximately 2 log10
cfu) of Mtb using an aerosol exposure system (CH Technology,
Inc., Westwood, NJ) as described previously [55]. CC-3052
(25 mg/kg) was administered 5 days per week by gavage, and
INH (50 mg/kg) was delivered ad libitum in drinking water.
Neutralizing anti-TNF-a antibody TN3-19.12 (500 mg/mouse)
and IgG1 isotype control (500 mg/mouse) were suspended in
300 ml of phosphate-buffered saline and administered by intra-
peritoneal injection once a week.
CFU and body weight
The numbers of viable mycobacteria were evaluated using colony
formingunits(CFU)assay.Forquantitationofinitialinoculum,lungs
wereisolatedfrommice3 hrspost-infection;lung homogenateswere
plated on 7H11 Middlebrook agar plates, incubated at 37uCf o r2 1
days, and colonies counted. Bacterial loads are presented as the
mean value in log10 6 standard deviation (SD). Body weight was
measured every 3 days and expressed in percent (%) change to body
weight at baseline (day 0). The Student’s t-test was used to determine
statistical significance between groups of data.
Histopathology, immunohistology and morphometric
analysis
Segments of lung tissue were fixed in 10% buffered formalin
(Sigma-Aldrich) and paraffin-embedded. Sections were stained
with Hematoxylin-Eosin (H&E) or Ziehl-Neelsen (ZN) acid-fast
stain for evaluation of pathology and mycobacterial load,
respectively. All photographs of the H&E and ZN stained sections
were taken and analyzed using Nikon FX-35DX and microphot-
FX. For morphometric analysis of granulomas in mouse lungs,
H&E stained lung sections (n=3–6 per group) were scanned with
a PathScan Enabler IV scanner (Meyer Instruments, Houston,
TX). SigmaScan Pro 5 software was used to count the number and
size of lesions. The extent of lung involvement was calculated using
three parameters: the average size of granulomas, the number of
lesions per cm
2 tissue, and the percent of the lung sections
occupied by granulomas. Morphometric analysis was carried out
by an independent single investigator blinded to the source of
tissues. Immunohistochemistry staining was done with polyclonal
anti-mouse CD3 antibody (Biocare Medical, Concord, CA). The
number of CD3
+ T cells was counted in 10640 fields by 2
independent investigators blinded to tissue sources.
DNA array and quantitative real time PCR
Global expression analysis of four independent arrays per group
was performed using Affymetrix mouse genome ST 1.0 genes chips.
For analysis, uninfected mice (baseline), untreated mice, CC-3052-
treated mice at 14, 21, 28 and 42 days after infection (n=4 per group)
were euthanized. RNA from mouse lungs was isolated with Trizol
(Invitrogen), DNase I treated, and further purified using RNeasy
miniprep kit (Qiagen). Microarray experiments were performed once
or twice and four independent arrays per group were analyzed. Data
reduction and analysis of comparison of treatment groups was
normalized, and filtered expression files were analyzed using Partek
Genomic Suite. SAM (significance analysis of microarray) tool was
used for adjusting the P values from a comparison test based on the
number of tests performed. Differentially expressed genes were
selected with a cutoff value of 61.5 fold change (P,0.05). Gene
ontology analysis was performed using Pathway Express (Wayne
State University, Detroit, MI). Reverse transcription of total lung
RNAfortheqPCRwascompletedwithafirst-strandcDNAsynthesis
k i tb yo l i g o( d T )p r i m i n g( I n v i t r o g e n ) ,a c c o r d i n gt ot h em a n u f a c t u r -
er’s protocol. Real time PCR was performed using the Invitrogen
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manufacturer. Primers specific to genes of interest were designed as
recommended by PrimerBank (www. primerbank.org). Quantified,
purified and diluted PCR product was used to generate external
standard curves for each primer pair. Cycle number values were
converted to copy number using these curves post-amplification.
qPCR of glyceraldehyde-3-phosphate dehydrogenase (gapdh)w a s
always run inparallel with that of the other genes of interest and levels
of gene expression measured were normalized to the housekeeping
gene gapdh. The complete gene lists are accessible through GEO
database, NCBI accession number GSE25313.
Single tissue cell preparation
Single cell suspensions from lung tissue were prepared by
incubating minced tissue with collagenase A (1 mg/ml; Boehrin-
ger-Mannheim) and DNase I (25–50 U/ml; Sigma-Aldrich) for
1 hour at 37uC. The digested lung was further disrupted by gentle
teasing through a cell strainer (BD Bioscience). Spleens were
disrupted by teasing the tissue directly through a cell strainer
without digestion. Red blood cells were lysed with ACK buffer
(GIBCO), washed and resuspended in RPMI 1640 medium
supplemented with 10% fetal calf serum (FCS), penicillin/
streptomycin (50 U/50 mg/ml; R10). Total number of cells was
determined by microscopic counting using a hemocytometer.
Spleen cells were cultured at 37uC at a density of 2.5610
5/100 ml
in 96-well U-bottom plates. The cells were stimulated in R10 with
Purified Protein Derivative (PPD, 10 mg/ml final; Staten Serum
Institute) or lipopolysaccharide (LPS, 1 mg/ml final; Sigma) and
incubated at 37uC for 6 hrs, 24 hrs or 6 days. At each time point,
culture supernatant was removed, filtered using 0.22 mm low-
binding microfuge filter tubes (Millipore, Billerica, MA) and stored
at 280uC for cytokine assays. Isolated cells were frozen at 280uC
in R10 with 10% DMSO for flow cytometric analysis.
Flow cytometric analysis of cell surface markers and
intracellular cytokine assay
Spleen or lungs were removed from CC-3052 treated or
untreated infected mice at the indicated time points and processed
as described [56]. Briefly, cells were stained with FITC-anti-CD14,
PE-anti-CD4, PercP-anti-CD3, and APC-anti-CD8 monoclonal
antibodies (BD Bioscience). For detection of intracellular TNF-a,
spleen cells, cultured in the presence of PPD (10 mg/ml final) for
6 hrs, were stained with PE-anti-IFN-c, ACP-anti-TNF-a, FITC-
anti-CD4, PercP-anti-CD3, APC-anti-CD8 and FITC-anti-CD14
(BD Biosciences, SanJose, CA). IntracellularIFN-c inlung cells was
measure without prior in vitro stimulation. Data acquisition and
analysis were performed using FACSCalibur (BD Bioscience) and
FlowJo software (Tree Star, Ashland, OR) respectively.
Proliferation assay
Spleen cells isolated as described above were stained with
carboxyfluorescein succinimidyl ester dye (CFSE; Invitrogen,
Carlsbad, CA), according to manufacturer’s instructions.
2.5610
5 CFSE-labeled cells/100 ml were plated in 96-well U-
bottom plates, and stimulated for 6 days with ConA (5 mg/ml final
concentration; Sigma) or heat-killed, sonicated Mtb CDC1551 at a
multiplicity of infection of 10 to 1 (MOI 10:1), or left unstimulated.
Cells were fixed and stored at 280uC. Cells were stained for
surface markers with the following mAbs: PE-anti-CD4, APC-anti-
CD8 and PerCP-anti-CD3 (BD Bioscience). Data acquisition and
analysis were performed using FACSCalibur (BD Bioscience) and
FlowJo software (Tree Star, Ashland, OR). Proliferation was
measured as a reduction in CFSE fluorescence intensity.
Statistical analysis
All data are presented as the mean 6 standard deviation (SD).
Statistical significance was determined using SAM (significance
analysis microarrays) and Student’s t-test. A value of P,0.05 was
considered significant.
Accession numbers
Detailed information for the genes/proteins from this study can
be found at NCBI GenBank database www.ncbi.nih.gov/genbank.
The gene name and ID numbers in this publication are listed in
Table S1. The ID numbers of TNF-a and IFN-c shown in this
publication are NP_038721 and AAI19061, respectively.
Supporting Information
Figure S1 Morphometric analysis of the extent of the
granulomatous infiltration in the lungs. H&E stained lung
sections from Mtb-infected mice with or without CC-3052 and/or
INH treatment at 35 or 63 days post-infection. The extent of the
lung tissue involved in granuloma formation was represented as (A)
the number of granulomas per cm
2 and (B) the percentage of lung
involved. Results shown are mean 6 SD from 3–4 mice per group
per time point.
(TIF)
Figure S2 Phenotype of lung cells isolated from infected
mice. Lung cells from mice infected for 28 days, with or without
CC-3052 treatment, were stained for T cell and macrophage
markers and analyzed by flow cytometry. (A) Representative dot




+ cells in the lungs. Data are expressed as the mean 6 SD of
8 replicates per untreated mice and 8 replicates per CC-3052
treated mice. (C) IFN-c producing CD4
+ and CD8
+ cells
(right panel). Data are expressed as the mean 6 SD of 2 mice
per group.
(TIF)
Table S1 Differentially expressed mouse genes by CC-3052
treatment. Gene expression was analyzed from total RNA of
uninfected and Mtb-infected mouse lungs, treated or not treated
with CC-3052, at 28 days post-infection. Results are representative
of 4 independent arrays per group and presented as relative gene
expression. Fold change ($1.5 fold) of differentially expressed
genes from arrays was statistically significant based on SAM




We would like to thank Dr. R. Schreiber at the University of Washington
in Saint Louis, MO for providing TN3-19.12 and IgG1 antibodies. We also
thank Leslie Taylor for immunohistochemistry staining of mouse lung
tissues and Sabrina Dalton for assisting in preparation of the manuscript.
We thank the staff of PHRI’s Center for Applied Genomics (CAG) for
assistance with the microarray analysis and the staff of the animal facility at
PHRI-UMDNJ for care of the experimental mice.
Author Contributions
Conceived and designed the experiments: MK DF GK. Performed the
experiments: MK CM PO NS LT. Analyzed the data: MK CM GY LT SS
SE GK. Contributed reagents/materials/analysis tools: GM. Wrote the
paper: MK CM DF GK. Provided the drug CC-3052: GM.
Effect of Immune Modulation on Murine Tuberculosis
PLoS ONE | www.plosone.org 12 February 2011 | Volume 6 | Issue 2 | e17091References
1. Global tuberculosis control: a short update to the 2009 report. World Health
Organization (2010).
2. Gomez JE, McKinney JD (2004) M. tuberculosis persistence, latency, and drug
tolerance. Tuberculosis (Edinb) 84: 29–44.
3. Kwara A, Flanigan TP, Carter EJ (2005) Highly active antiretroviral therapy
(HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 9:
248–257.
4. Connolly LE, Edelstein PH, Ramakrishnan L (2007) Why is long-term therapy
required to cure tuberculosis? PLoS Med 4: e120.
5. McKinney JD (2000) In vivo veritas: the search for TB drug targets goes live.
Nat Med 6: 1330–1333.
6. Jain SK, Lamichhane G, Nimmagadda S, Pomper MG, Bishai WR (2008)
Antibiotic Treatment of Tuberculosis: Old Problems, New Solutions. Microbe 3:
285–292.
7. Chao MC, Rubin EJ (2010) Letting sleeping dos lie: does dormancy play a role
in tuberculosis? Annu Rev Microbiol 64: 293–311.
8. Dhar N, McKinney JD (2007) Microbial phenotypic heterogeneity and
antibiotic tolerance. Curr Opin Microbiol 10: 30–38.
9. Nathan C, Ehrt S (2004) Nitric oxide in tuberculosis. In: Rom WN, Garray SM,
eds. Tuberculosis. Philadelphia: Lippincott Williams & Wilkins. pp 215–235.
10. Bartek IL, Rutherford R, Gruppo V, Morton RA, Morris RP, et al. (2009) The
DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis
(Edinb) 89: 310–316.
11. Shi L, Sohaskey CD, North RJ, Gennaro ML (2008) Transcriptional
characterization of the antioxidant response of Mycobacterium tuberculosis in
vivo and during adaptation to hypoxia in vitro. Tuberculosis (Edinb) 88: 1–6.
12. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, et al. (2003)
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages:
Insights into the Phagosomal Environment. J Exp Med 198: 693–704.
13. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al.
(2003) Inhibition of respiration by nitric oxide induces a Mycobacterium
tuberculosis dormancy program. J Exp Med 198: 705–713.
14. Chan J, Xing Y, Magliozzo RS, Bloom BR (1992) Killing of virulent
Mycobacterium tuberculosis by reactive nitrogen intermediates produced by
activated murine macrophages. J Exp Med 175: 1111–1122.
15. Muthuswamy P, Hu TC, Carasso B, Antonio M, Dandamudi N (1995)
Prednisone as adjunctive therapy in the management of pulmonary tuberculosis.
Report of 12 cases and review of the literature. Chest 107: 1621–1630.
16. Wallis RS (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin
Infect Dis 41: 201–208.
17. Mayanja-Kizza H, Jones-Lopez E, Okwera A, Wallis RS, Ellner JJ, et al. (2005)
Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase
2 clinical trial in Uganda. J Infect Dis 191: 856–865.
18. Horne NW (1960) Prednisolone in treatment of pulmonary tuberculosis: a
controlled trial. Final report to the Research Committee of the Tuberculosis
Society of Scotland. Br Med J 2: 1751–1756.
19. Bilaceroglu S, Perim K, Buyuksirin M, Celikten E (1999) Prednisolone: a
beneficial and safe adjunct to antituberculosis treatment? A randomized
controlled trial. Int J Tuberc Lung Dis 3: 47–54.
20. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, et al. (2004) A study
of the safety, immunology, virology, and microbiology of adjunctive etanercept
in HIV-1-associated tuberculosis. AIDS 18: 257–264.
21. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel
antiasthma agents. Am J Respir Crit Care Med 157: 351–370.
22. Guckian M, Dransfield I, Hay P, Dalgleish AG (2000) Thalidomide analogue
CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol 121:
472–479.
23. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, et al. (1998) CC-
3052: a water-soluble analog of thalidomide and potent inhibitor of activation-
induced TNF-alpha production. J Immunol 161: 4236–4243.
24. Hertz AL, Bender AT, Smith KC, Gilchrist M, Amieux PS, et al. (2009)
Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in
human monocyte-derived macrophages. Proc Natl Acad Sci U S A 106:
21978–21983.
25. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, et al. (1999)
Differential cytokine modulation and T cell activation by two distinct classes of
thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:
380–386.
26. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, et al. (2002)
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha
and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp
Immunol 130: 75–84.
27. Fan Chung K (2006) Phosphodiesterase inhibitors in airways disease.
Eur J Pharmacol 533: 110–117.
28. Manca C, Tsenova L, Barry CE, 3rd, Bergtold A, Freeman S, et al. (1999)
Mycobacterium tuberculosis CDC1551 induces a more vigorous host response
in vivo and in vitro, but is not more virulent than other clinical isolates.
J Immunol 162: 6740–6746.
29. McCune RM, Tompsett R, McDermott W (1956) Fate of Mycobacterium
tuberculosis in mouse tissues as determined by the microbial enumeration
technique. I. The persistence of drug susceptible bacilli in the tissues despite
prolonged antimicrobial therapy. J Exp Med 104: 737–762.
30. McCune RM, Tompsett R (1956) Fate of Mycobacterium tuberculosis in mouse
tissues as determined by the microbial enumeration technique. II. The
conversion of tuberculosis infection to the latent state by the administration of
tuberculosis and a companion drug. J Exp Med 104: 763–802.
31. Shi L, Jung YJ, Tyagi S, Gennaro ML, North RJ (2003) Expression of Th1-
mediated immunity in mouse lungs induces a Mycobacterium tuberculosis
transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad
Sci U S A 100: 241–246.
32. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19:
93–129.
33. Gonzalez-Juarrero M, Kingry LC, Ordway DJ, Henao-Tamayo M, Harton M,
et al. (2009) Immune response to Mycobacterium tuberculosis and identification
of molecular markers of disease. Am J Respir Cell Mol Biol 40: 398–409.
34. Bloom BR, Flynn J, McDonough K, Kress Y, Chan J (1994) Experimental
approaches to mechanisms of protection and pathogenesis in M. tuberculosis
infection. Immunobiology 191: 526–536.
35. Saunders BM, Britton WJ (2007) Life and death in the granuloma:
immunopathology of tuberculosis. Immunol Cell Biol 85: 103–111.
36. Nussler AK, Billiar TR, Liu ZZ, Morris SM, Jr. (1994) Coinduction of nitric
oxide synthase and argininosuccinate synthetase in a murine macrophage cell
line. Implications for regulation of nitric oxide production. J Biol Chem 269:
1257–1261.
37. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V (2008) Toll-like
receptors control autophagy. EMBO J 27: 1110–1121.
38. Thorn CF, Whitehead AS (2002) Differential transcription of the mouse acute
phase serum amyloid A genes in response to pro-inflammatory cytokines.
Amyloid 9: 229–236.
39. Shi S, Blumenthal A, Hickey CM, Gandotra S, Levy D, et al. (2005) Expression
of many immunologically important genes in Mycobacterium tuberculosis-
infected macrophages is independent of both TLR2 and TLR4 but dependent
on IFN-alphabeta receptor and STAT1. J Immunol 175: 3318–3328.
40. Raasi S, Schmidtke G, Groettrup M (2001) The ubiquitin-like protein FAT10
forms covalent conjugates and induces apoptosis. J Biol Chem 276:
35334–35343.
41. van Crevel R, Ottenhoff TH, van der Meer JW (2002) Innate immunity to
Mycobacterium tuberculosis. Clin Microbiol Rev 15: 294–309.
42. Sheehan KC, Ruddle NH, Schreiber RD (1989) Generation and characteriza-
tion of hamster monoclonal antibodies that neutralize murine tumor necrosis
factors. J Immunol 142: 3884–3893.
43. McCune RM, Feldmann FM, Lambert HP, McDermott W (1966) Microbial
persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse
tissues. J Exp Med 123: 445–468.
44. Bryk R, Gold B, Venugopal A, Singh J, Samy R, et al. (2008) Selective killing of
nonreplicating mycobacteria. Cell Host Microbe 3: 137–145.
45. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR (2009) Cyclic AMP
intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase.
Nature 460: 98–102.
46. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor
necrosis factor-alpha is required in the protective immune response against
Mycobacterium tuberculosis in mice. Immunity 2: 561–572.
47. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, et al. (1999) Reactivation of
latent tuberculosis: variations on the Cornell murine model. Infect Immun 67:
4531–4538.
48. Harris J, Keane J (2010) How tumour necrosis factor blockers interfere with
tuberculosis immunity. Clin Exp Immunol 161: 1–9.
49. Mootoo A, Stylianou E, Arias MA, Reljic R (2009) TNF-alpha in tuberculosis: a
cytokine with a split personality. Inflamm Allergy Drug Targets 8: 53–62.
50. Ray JC, Flynn JL, Kirschner DE (2009) Synergy between individual TNF-
dependent functions determines granuloma performance for controlling
Mycobacterium tuberculosis infection. J Immunol 182: 3706–3717.
51. Grosset J (2003) Mycobacterium tuberculosis in the extracellular compartment:
an underestimated adversary. Antimicrob Agents Chemother 47: 833–836.
52. Paige C, Bishai WR (2010) Penitentiary or penthouse condo: the tuberculous
granuloma from the microbe’s point of view. Cell Microbiol 12: 301–309.
53. Bekker LG, Maartens G, Steyn L, Kaplan G (1998) Selective increase in plasma
tumor necrosis factor-alpha and concomitant clinical deterioration after
initiating therapy in patients with severe tuberculosis. J Infect Dis 178: 580–584.
54. Marino S, Sud D, Plessner H, Lin PL, Chan J, et al. (2007) Differences in
reactivation of tuberculosis induced from anti-TNF treatments are based on
bioavailability in granulomatous tissue. PLoS Comput Biol 3: 1909–1924.
55. Tsenova L, Moreira A, Party E, Freedman VH, Kaplan G (1997) Aerosol
infection of mice with a nose-only exposure device. J Am Biol Safety Assoc 2:
20–31.
56. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, et al. (1999) Mice
deficient in CD4 T cells have only transiently diminished levels of IFN-gamma,
yet succumb to tuberculosis. J Immunol 162: 5407–5416.
Effect of Immune Modulation on Murine Tuberculosis
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e17091